Sonoma Pharmaceuticals (SNOA)
(Real Time Quote from BATS)
$0.15 USD
-0.01 (-5.66%)
Updated Apr 29, 2024 11:30 AM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Income Statements
Fiscal Year end for Sonoma Pharmaceuticals, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 13 | 13 | 19 | 19 |
Cost Of Goods | NA | 9 | 9 | 12 | 11 |
Gross Profit | NA | 4 | 4 | 7 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 9 | 10 | 10 | 15 |
Income After Depreciation & Amortization | 0 | -5 | -6 | -3 | -7 |
Non-Operating Income | NA | -1 | 0 | 0 | 4 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -5 | -5 | -4 | -3 |
Income Taxes | NA | 0 | 0 | 1 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -5 | -5 | -5 | -3 |
Extras & Discontinued Operations | NA | 0 | 0 | 1 | 0 |
Net Income (GAAP) | NA | -5 | -5 | -4 | -3 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -4 | -6 | -3 | -6 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -5 | -6 | -3 | -7 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 3.39 | 2.65 | 2.00 | 1.48 |
Diluted EPS Before Non-Recurring Items | NA | -1.09 | -1.92 | -2.31 | -3.90 |
Diluted Net EPS (GAAP) | NA | -1.52 | -1.92 | -1.97 | -1.99 |
Fiscal Year end for Sonoma Pharmaceuticals, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.14 | 2.73 | 3.43 | 3.01 |
Cost Of Goods | NA | 1.68 | 1.74 | 2.22 | 2.15 |
Gross Profit | NA | 1.46 | 0.99 | 1.20 | 0.86 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.30 | 2.20 | 2.45 | 2.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.84 | -1.21 | -1.25 | -1.15 |
Non-Operating Income | NA | -0.08 | -0.09 | -0.21 | -0.29 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -0.92 | -1.30 | -1.45 | -1.44 |
Income Taxes | NA | -0.06 | 0.19 | -0.03 | -0.13 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.87 | -1.48 | -1.42 | -1.31 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.87 | -1.48 | -1.42 | -1.31 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 10.91 | 5.16 | 4.94 | 4.26 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.20 | -0.29 | -0.23 |
Diluted Net EPS (GAAP) | NA | -0.08 | -0.29 | -0.29 | -0.28 |